PYRIDOSTIGMINE BROMIDE tablet

Страна: Соединенные Штаты

Язык: английский

Источник: NLM (National Library of Medicine)

Активный ингредиент:

PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNII:19QM69HH21)

Доступна с:

Method Pharmaceuticals, LLC

Администрация маршрут:

ORAL

Тип рецепта:

PRESCRIPTION DRUG

Терапевтические показания :

Pyridostigmine bromide tablets are useful in the treatment of myasthenia gravis. Pyridostigmine bromide tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

Обзор продуктов:

Tablets, are available as white, flat-faced tablets containing 30 mg pyridostigmine bromide, USP in bottles of 21 (NDC 58657-810-21) and cartons of 30 (3 x 10 blister packs - NDC 58657-810-30) and cartons of 210 tablets (21 blister cards of 10 tablets - NDC 58657-810-10). Each tablet is White to off white, round, flat tablet, debossed IT above bisect and 106 below bisect on one side, other side is plain. Store pyridostigmine bromide tablets, USP at 25°C (77°F); excursions permitted to 15° -30°C (59° -86°F) [See USP Controlled Room Temperature]. Keep pyridostigmine bromide tablets, USP in a dry place with the silica gel enclosed

Статус Авторизация:

Abbreviated New Drug Application

Характеристики продукта

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE TABLET
METHOD PHARMACEUTICALS, LLC
----------
PYRIDOSTIGMINE BROMIDE TABLETS
PYRIDOSTIGMINE BROMIDE TABLETS
Method Pharmaceuticals, LLC
----------
PYRIDOSTIGMINE BROMIDE TABLETS
DESCRIPTION
Pyridostigmine bromide tablets, USP (pyridostigmine bromide) are an
orally active
cholinesterase inhibitor. Chemically, pyridostigmine bromide is
3-hydroxy-1-
methylpyridinium bromide dimethylcarbamate. Its structural formula is:
Pyridostigmine bromide tablets,USP are available in the following
form:
Tablets containing 30 mg pyridostigmine bromide; each tablet also
contains anhydrous
lactose, colloidal silicon dioxide and stearic acid.
CLINICAL PHARMACOLOGY
Pyridostigmine bromide tablets inhibits the destruction of
acetylcholine by cholinesterase
and thereby permits freer transmission of nerve impulses across the
neuromuscular
junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but
differs from it in
certain clinically significant respects; for example, pyridostigmine
is characterized by a
longer duration of action and fewer gastrointestinal side effects.
INDICATIONS AND USAGE
Pyridostigmine bromide tablets are useful in the treatment of
myasthenia gravis.
CONTRAINDICATIONS
Pyridostigmine bromide tablets are contraindicated in mechanical
intestinal or urinary
obstruction, and particular caution should be used in its
administration to patients with
bronchial asthma. Care should be observed in the use of atropine for
counteracting side
effects, as discussed below.
WARNINGS
Although failure of patients to show clinical improvement may reflect
under dosage, it
can also be indicative of overdosage. As is true of all cholinergic
drugs, overdosage of
pyridostigmine bromide may result in cholinergic crisis, a state
characterized by
increasing muscle weakness which, through involvement of the muscles
of respiration,
may lead to death. Myasthenic crisis due to an increase in the
severity of the disease is
also accompanied by extreme muscle weakness, and thus may be difficult